CAMBRIDGE, Mass., Oct. 30, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced its financial results and business highlights for the third-quarter and first nine-months of 2013.
Help employers find you! Check out all the jobs and post your resume.
